|
**Overview**: Autoimmune-Hepatitis Panel**Introduction**: The Autoimmune-Hepatitis Panel is a diagnostic tool designed to screen for autoimmune hepatitis using serum samples. In India, autoimmune hepatitis (AIH) affects 1-5 per 100,000, with type 1 (ANA/ASMA positive) more common in women and type 2 (anti-LKM1) in children. High prevalence in northern states, association with viral hepatitis overlap, and underdiagnosis in rural areas due to nonspecific symptoms like fatigue, jaundice, arthralgia. High morbidity from delayed diagnosis leading to cirrhosis or liver failure. Per gastroenterology practices aligned with ICMR and Indian National Association for Study of the Liver guidelines, the test employs immunoassay for antibody detection over 1-2 days with high sensitivity/specificity, valuable for confirming AIH and guiding steroids/azathioprine. This diagnostic falls under liver disorder screening and targets patients with unexplained hepatitis, addressing accurate detection to prevent progression. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing cirrhosis burden. Its serum-based approach ensures reliable detection.**Other Names**: Auto Hep Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Antibody profiles standardized; in India, prominence with rising AIH cases.**Purpose**: The test screens for 8 parameters including ANA to guide AIH diagnosis, assess autoimmunity, inform immunosuppressive therapy.**Test Parameters**: 1. ANA, 2. Anti-Smooth Muscle Ab, 3. Anti-LKM1, 4. Anti-Mitochondrial Ab, 5. Anti-SLA/LP, 6. Anti-Factin, 7. Anti-Sp100, 8. Anti-gp210.**Pretest Condition**: No fasting required; patients should report fatigue, jaundice, arthralgia, or elevated liver enzymes.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on jaundice, fatigue, family autoimmune history, viral hepatitis exposure.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated AIH including cirrhosis, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent viral hepatitis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive antibodies indicate AIH, necessitating specialist input. Negative may require follow-up if liver enzymes elevated.**Specialist Consultation**: Hepatologists or gastroenterologists should be consulted for management.**Additional Supporting Tests**: Liver biopsy, IgG levels for confirmation.**Test Limitations**: May overlap with other liver diseases; comprehensive approach required.**References**: Indian Journal of Gastroenterology 2024, AIH Studies India 2023. |
